Comparative Pharmacology
Head-to-head clinical analysis: THAM versus THAM E.
Head-to-head clinical analysis: THAM versus THAM E.
THAM vs THAM-E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
THAM (tromethamine) is a proton acceptor that buffers hydrogen ions, treating metabolic acidosis by increasing blood pH and bicarbonate buffering capacity.
THAM-E (tromethamine) is a sodium-free organic amine that acts as a proton acceptor, buffering excess hydrogen ions in metabolic acidosis. It increases bicarbonate concentration by reducing carbon dioxide tension and enhances renal excretion of hydrogen ions.
Intravenous administration of 300-500 mL of 0.3 M THAM solution (approximately 1-2 mEq/kg) over 30-60 minutes, repeated as needed based on blood pH and base deficit.
Intravenous: Initial dose (mL of 0.3 M solution) = body weight (kg) × base deficit (mEq/L) × 1.1. Administer by slow IV infusion, not to exceed 8 mL/kg/hour. Maximum single dose: 48 mL/kg.
None Documented
None Documented
Clinical Note
moderateMechlorethamine + Digoxin
"Mechlorethamine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMechlorethamine + Digitoxin
"Mechlorethamine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMechlorethamine + Deslanoside
"Mechlorethamine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMechlorethamine + Acetyldigitoxin
"Mechlorethamine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: 1-2 hours in patients with normal renal function; prolonged up to 6-8 hours in renal impairment.
Terminal elimination half-life: 5-10 minutes (2-3 minutes for distribution phase). Clinically negligible accumulation with repeat doses due to rapid renal clearance.
Renal: >95% excreted unchanged in urine. Biliary/fecal: negligible (<5%).
Renal: >95% as unchanged drug; <5% metabolized or excreted in bile/feces.
Category C
Category C
Alkalizing Agent
Alkalizing Agent